Pfizer [PFE] vs Amgen [AMGN] Detailed Stock Comparison

Pfizer Inc.

NYSE
Loading...

Amgen Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Pfizer Inc. wins in 11 metrics, Amgen Inc. wins in 10 metrics, with 0 ties. Pfizer Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pfizer Inc. Amgen Inc. Better
P/E Ratio (TTM) 19.61 24.22 Pfizer Inc.
Price-to-Book Ratio 1.75 21.46 Pfizer Inc.
Debt-to-Equity Ratio 77.96 640.28 Pfizer Inc.
PEG Ratio -0.04 0.22 Amgen Inc.
EV/EBITDA 8.01 13.97 Pfizer Inc.
Profit Margin (TTM) 12.42% 20.98% Amgen Inc.
Operating Margin (TTM) 23.95% 30.55% Amgen Inc.
EBITDA Margin (TTM) 23.95% 30.55% Amgen Inc.
Return on Equity 8.89% 106.10% Amgen Inc.
Return on Assets (TTM) 5.68% 7.93% Amgen Inc.
Free Cash Flow (TTM) $9.08B $8.10B Pfizer Inc.
Dividend Yield 6.71% 3.30% Pfizer Inc.
1-Year Return 6.81% 20.32% Amgen Inc.
Price-to-Sales Ratio (TTM) 2.42 5.06 Pfizer Inc.
Enterprise Value $206.00B $232.21B Amgen Inc.
EV/Revenue Ratio 3.29 6.32 Pfizer Inc.
Gross Profit Margin (TTM) 69.97% 69.84% Pfizer Inc.
Revenue per Share (TTM) $11 $68 Amgen Inc.
Earnings per Share (Diluted) $1.36 $14.24 Amgen Inc.
Beta (Stock Volatility) 0.39 0.47 Pfizer Inc.
Short % of Float 2.33% 2.60% Pfizer Inc.

Pfizer Inc. vs Amgen Inc. Stock Performance Analysis

Loading Price Chart...

PFE
AMGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pfizer Inc.-0.80%1.48%2.65%-2.29%-1.63%3.26%
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pfizer Inc.6.81%-34.57%-32.47%-19.28%36.37%17.90%
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%

Performance & Financial Health Analysis: Pfizer Inc. vs Amgen Inc.

MetricPFEAMGN
Market Information
Market Cap i$153.59B$187.93B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i30,662,9312,431,753
90 Day Avg. Volume i36,790,7552,596,291
Last Close$26.00$350.53
52 Week Range$23.11 - $28.75$267.83 - $391.29
% from 52W High-9.57%-10.42%
All-Time High$61.71 (Dec 20, 2021)$391.29 (Mar 02, 2026)
% from All-Time High-57.87%-10.42%
Growth Metrics
Quarterly Revenue Growth-0.01%0.09%
Quarterly Earnings Growth-0.01%1.13%
Financial Health
Profit Margin (TTM) i0.12%0.21%
Operating Margin (TTM) i0.24%0.31%
Return on Equity (TTM) i0.09%1.06%
Debt to Equity (MRQ) i77.96640.28
Cash & Liquidity
Book Value per Share (MRQ)$15.21$16.07
Cash per Share (MRQ)$2.39$16.94
Operating Cash Flow (TTM) i$11.70B$9.96B
Levered Free Cash Flow (TTM) i$13.43B$7.50B
Dividends
Last 12-Month Dividend Yield i6.71%3.30%
Last 12-Month Dividend i$1.72$12.18

Valuation & Enterprise Metrics Analysis: Pfizer Inc. vs Amgen Inc.

MetricPFE (Apr 26, 2026)AMGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.6124.22
Forward P/E i9.4814.77
PEG Ratio i-0.040.22
Price to Sales (TTM) i2.425.06
Price to Book (MRQ) i1.7521.46
Market Capitalization
Market Capitalization i$153.59B$187.93B
Enterprise Value i$206.00B$232.21B
Enterprise Value Metrics
Enterprise to Revenue i3.296.32
Enterprise to EBITDA i8.0113.97
Risk & Other Metrics
Beta i0.390.47
Book Value per Share (MRQ) i$15.21$16.07

Financial Statements Comparison: Pfizer Inc. vs Amgen Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPFE (2025)AMGN (2025)
Revenue/Sales i62.58B36.75B
Cost of Goods Sold i16.07B12.04B
COGS % of Revenue i25.7%32.8%
Gross Profit i46.51B24.71B
Gross Margin i74.3%67.2%
Research & Development i10.44B7.27B
Operating Income (EBIT) i17.41B9.08B
Operating Margin i27.8%24.7%
EBITDA i25.75B16.90B
EBITDA Margin i41.1%46.0%
Pre-Tax Income i7.52B8.98B
Pre-Tax Income % of Revenue i12.0%24.4%
Income Tax i-266.00M1.27B
Income Tax % of Revenue i-0.4%3.4%
Net Income (Profit) i7.81B7.71B
Profit Margin i12.5%21.0%

Balance Sheet & Liquidity Metrics

MetricPFE (2025)AMGN (2025)
Cash & Equivalents i1.14B9.13B
Total Current Assets i42.90B29.06B
Total Current Assets % of Revenue i68.6%79.1%
Total Current Liabilities i36.98B25.49B
Total Current Liabilities % of Revenue i59.1%69.4%
Long-Term Debt i60.81B50.01B
Long-Term Debt % of Revenue i97.2%136.1%
Total Shareholders Equity i86.78B8.66B
Retained Earnings i114.61B-25.11B
Retained Earnings % of Revenue i183.1%-68.3%
Property, Plant & Equipment i05.22B

Cash Flow Statement Comparison

MetricPFE (2025)AMGN (2025)
Operating Cash Flow i6.43B10.51B
Operating Cash Flow % of Revenue i10.3%28.6%
Capital Expenditures i-2.63B-1.86B
Free Cash Flow i9.08B8.10B
FCF Margin i14.5%22.0%
Debt Repayment i-9.75B-5.00B
Common Stock Repurchase iN/A0

Short Interest & Institutional Ownership Analysis

MetricPFEAMGN
Shares Short i132.47M13.98M
Short Ratio i3.175.43
Short % of Float i2.33%2.60%
Shares Outstanding i5.69B538.80M
Float Shares i5.68B537.62M
% Held by Insiders i0.10%0.22%
% Held by Institutions i68.38%85.36%
% Held by Public i31.52%14.42%

Dividend Analysis & Yield Comparison: Pfizer Inc. vs Amgen Inc.

MetricPFEAMGN
Last 12-Month Dividend i$1.72$12.18
Last 12-Month Dividend Yield i6.71%3.30%
3-Year Avg Annual Dividend i$1.69$9.98
3-Year Avg Dividend Yield i1.54%0.77%
3-Year Total Dividends i$5.06$29.95
Ex-Dividend DateJan 23, 2026May 15, 2026